Brought to you by 
Currax acquires Nalpropion, gaining weight-loss medicine Contrave
31 Aug 2020
Executive Summary
Currax Pharmaceuticals LLC acquired 2018 start-up Nalpropion Pharmaceuticals Inc.. gaining worldwide rights to Nalpropion's sole product, the FDA-approved Contrave (bupropion/naltrexone; sold in the EU as Mysimba) weight-loss medication.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Currax acquires Nalpropion, gaining weight-loss medicine Contrave
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice